Navigating the ADC Development Pathway
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges.
In this webinar, experts discuss approaches for target validation and strategies to address ADC bioanalytical and DMPK challenges. Further discussion focuses on approaches for nonclinical safety evaluation, underscoring the need to assess both intact ADCs and novel payloads in relevant animal models. This webinar offers a comprehensive perspective on strategies crucial to accelerating research and development of antibody-drug conjugates.
You May Also Be Interested In
Discuss Your Program with Us
Share your development goals and key challenges with our experts to define the right path forward.